Dr. Kyung-Hwa Park, a professor of medical oncology at Korea University Anam Hospital, emphasized the challenges faced by high-risk patients. “While early breast cancer generally has a high survival rate, outcomes can significantly worsen for those at high risk of recurrence,” she said. “Particularly for HR+/HER2- breast cancer, the risk of recurrence peaks within the first one to two years, and residual micrometastases post-surgery necessitate aggressive treatment.”
Dr. Park also highlighted a concerning trend: the rising incidence of breast cancer among women in their 30s and 40s. “Recurrence imposes a heavy burden on patients, their families, and society,” she noted. “Economic constraints often lead patients to forgo treatment, which is a critical issue.”
The session also underscored the clinical efficacy of Verzenio combined with endocrine therapy. Dr. Park cited data from the monarchE trial, stating, “Verzenio, when used in combination with endocrine therapy for two years, significantly reduced the risk of recurrence. Five-year data from the trial confirm sustained benefits.”
Mira Kwon, executive director of Lilly Korea’s oncology division, reaffirmed the company’s commitment. “We are dedicated to improving patients’ quality of life and enhancing access to treatment through multifaceted efforts,” she said.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
